Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Haemacure and Baxter reach settlement:

This article was originally published in Clinica

Executive Summary

Canadian biomaterial company Haemacure has reached a C$2.3 million ($1.5 million) settlement with Baxter International, the supplier of Hemaseel APR fibrin sealant, payable to Haemacure. The settlement amount was credited against the licence fee of C$3.8 million payable to Baxter. The dispute concerned the cost of the product and other financial issues in the companies' manufacturing agreement. The cost review was carried out by a trustee appointed by the US Federal Trade Commission at Haemacure's request. The two companies have also agreed fixed prices for the remainder of the manufacturing agreement.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT072769

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel